Reviva: 108 patients complete 1-year brilaroxazine OLE; topline data expected Dec 2024

REVIVA PHARMACEUTICALS HOLDINGS, INC.

108 patients completed 12-month treatment; over 250 completed 6 months in the OLE study.
Long-term safety data from 100 patients with 12 months treatment now available for planned NDA submission.
Brilaroxazine continues to be generally well tolerated in acute and stable schizophrenia patients.
Topline 12-month long-term safety and efficacy data expected in December 2024.
OLE study (RECOVER) completion anticipated in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.